In addition, research continues to uncover new clues to identify which men are at highest
risk of aggressive prostate cancer and could most benefit from screening and treatment.
«Genetic association with aggressive prostate cancer discovered: Study showed a threefold increase in the risk
of aggressive prostate cancer for men with the genetic mutation..»
But although the drug, called finasteride, caused a 25 % reduction in prostate cancer, it also boosted the risk
of aggressive prostate cancer among those diagnosed with the disease.
«Breakthroughs in understanding the genetic
basis of aggressive prostate cancer: New research shows how losing a ubiquitous gene opens genetic floodgates that make prostate cancer deadly, a finding that could apply to many cancers..»
A study of almost 150,000 men from 8 European countries, presented at this year's European Obesity Summit (Gothenburg, 1 - 4 June) shows that higher body mass index (BMI) and waist circumference are associated with an increased risk
of aggressive prostate cancer.
Even more troubling, her study found a link between high blood levels of lycopene's chemical cousin, beta - carotene, and an increased risk
of aggressive prostate cancer — not enough to justify avoiding carrots and other food sources of beta - carotene but an ominous sign that not all food - derived compounds are necessarily benign when taken at higher doses.
In a new study published in The Journal of Urology ®, researchers determined that men who followed a Mediterranean diet, rich in fish, boiled potatoes, whole fruits, vegetables, legumes, and olive oil, and low consumption of juices had lower risk
of aggressive prostate cancer (PC) than those who followed other dietary patterns like Prudent or Western diets.
«Testosterone therapy does not raise risk
of aggressive prostate cancer.»
A new population - based study from The University of Texas Medical Branch at Galveston showed for the first time that exposure to testosterone therapy over a five - year period was not associated with an increased risk
of aggressive prostate cancer.